相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis
Justin S. A. Perry et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
James P. Sheridan et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
Simone C. Wuest et al.
NATURE MEDICINE (2011)
Different functional outcomes of intercellular membrane transfers to monocytes and T cells
Kiave-Yune HoWangYin et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
Jayne F. Martin et al.
JOURNAL OF IMMUNOLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. (vol 9, pg 381, 2010)
D. Wynn et al.
LANCET NEUROLOGY (2010)
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
Daniel Wynn et al.
LANCET NEUROLOGY (2010)
Capture of plasma membrane fragments from target cells by trogocytosis requires signaling in T cells but not in B cells
Anne Aucher et al.
BLOOD (2008)
Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes
Paul V. Beum et al.
JOURNAL OF IMMUNOLOGY (2008)
Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Tb1/Th2 cytokine production
James T. Snyder et al.
BLOOD (2007)
Trogocytosis-based generation of suppressive NK cells
Julien Caumartin et al.
EMBO JOURNAL (2007)
Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells
Joel LeMaoult et al.
BLOOD (2007)
Drug Insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis
Ronald P. Taylor et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2007)
Anti-tac (daclizumab, zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey
Thomas A. Waldmann
JOURNAL OF CLINICAL IMMUNOLOGY (2007)
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
What is trogocytosis and what is its purpose?
E Joly et al.
NATURE IMMUNOLOGY (2003)
分享论文
